Xoma Royalty Corp (XOMA) Q4 2025 Earnings Call Transcript

Why It Matters

The results de‑risk zanidatumab’s commercial trajectory and unlock substantial non‑dilutive financing, positioning Zymeworks for accelerated growth and strategic flexibility.

Key Takeaways

• Revenue $106M, up from $76.3M.
• Net loss narrowed to $81.1M.
• $250M royalty note secures 30% of zanidatumab royalties.
• Milestone upside $1.5B across Jazz, BeiGene collaborations.
• Phase III zanidatumab shows >1‑yr PFS, >2‑yr OS.

Pulse Analysis

Zanidatumab’s Phase III outcomes represent a rare breakthrough in HER2‑positive gastro‑esophageal adenocarcinoma, delivering median progression‑free survival beyond twelve months and overall survival exceeding two years. Such efficacy not only differentiates the ADC from existing HER2 therapies but also strengthens the case for regulatory approvals across multiple regions. The data’s consistency across sub‑groups, irrespective of PD‑L1 status, suggests a broad patient applicability that could drive rapid uptake once the supplemental BLA is filed under the FDA’s Real‑Time Oncology Review pathway.

Financially, Zymeworks has leveraged the clinical momentum to secure a $250 million royalty‑backed note from Royalty Pharma, a structure that ties repayment to only 30% of the zanidatumab royalty stream. This non‑recourse financing preserves 70% of future royalty cash flow, providing low‑cost, nondilutive capital while keeping the upside fully intact. Coupled with a projected cash runway extending beyond 2028 and an active share‑repurchase program, the company is positioned to fund ongoing R&D, pursue strategic acquisitions, and reinforce shareholder returns without compromising its long‑term royalty earnings.

From a market perspective, the combined royalty framework with Jazz and BeiGene unlocks up to $1.5 billion in milestone potential, including $440 million tied to regulatory approvals and nearly $1 billion linked to sales thresholds. As zanidatumab advances into additional indications such as metastatic breast cancer, the tiered royalty rates—ranging from mid‑single to high‑teen percentages and escalating above $1‑2 billion in sales—promise a multibillion‑dollar revenue runway. This blend of robust clinical data, innovative financing, and expansive partnership terms positions Zymeworks as a compelling player in the ADC space, attracting both investors and potential acquisition targets.